Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of two different doses of glycopyrronium GP metered-dose inhaler MDI compared to a placebo MDI when added to budesonide and formoterol fumarate BFF MDI in children aged 4 to less than 12 years with asthma. This Phase II, multi-center, randomized, double-blind crossover study aims to assess lung function improvements with these treatments. The study includes participants who have a history of physician-diagnosed asthma and are currently on stable inhaled corticosteroids plus an additional asthma controller medication. Participants undergo a 3-week run-in period followed by three 3-week treatment periods where they receive each of the three treatments in a randomized sequence BFF MDI with GP MDI Dose A, BFF MDI with GP MDI Dose B, and BFF MDI with placebo MDI. All medications are administered via oral inhalation twice daily. After the treatment periods, there is a safety follow-up visit 12 to 16 days after the last dose of study intervention. During the study, participants attend scheduled visits for assessments including lung function tests measuring forced expiratory volume in one second FEV1 at one hour post-dose and morning pre-dose trough FEV1 at the end of treatment. Researchers monitor safety and efficacy outcomes throughout the trial, which lasts approximately 12 weeks including the run-in and treatment periods plus follow-up. The study is designed to better understand the potential benefits and safety of adding different doses of GP MDI to standard asthma treatment in pediatric patients.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VE303, a live biotherapeutic product, in preventing the recurrence of Clostridioides difficile infection CDI. This study focuses on participants with either recurrent CDI or primary CDI at high risk for recurrence, assessing the recurrence rate at 8 weeks after treatment. The study is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Vedanta Biosciences, Inc. Participants receive either VE303 or a matching placebo after completing 10 to 21 days of standard antibiotic treatment for their CDI episode. Those assigned to the VE303 group take 3 capsules daily for 14 days the placebo group takes 3 placebo capsules daily for the same duration. The capsules look identical to ensure blinding. This treatment period follows the completion of their initial antibiotic therapy. Throughout the study, participants are monitored for CDI recurrence up to 8 weeks after treatment. Researchers evaluate safety and measure the rate of CDI coming back during this period. Participants must have completed standard antibiotic therapy and meet clinical stability criteria before starting the study drug. The total participation time includes screening, treatment, and observation phases until the primary outcome at week 8 is assessed.